34 results about "Phosphatidic acid" patented technology

An engineered microorganism comprising (i) a heterologous nucleic acid encoding a first lysophosphatidic acid acyltransferase (LPAAT) and (ii) a heterologous nucleic acid encoding a glycerol-3-phosophate acyltransferase (GPAT), a diacylglycerol acyltransferase (DGAT), or a second LPAAT; or a microorganism comprises (i) a heterologous nucleic acid encoding a first lysophosphatidic acid acyltransferase (LPAAT), and (ii) a heterologous nucleic acid encoding a glycerol-3-phosophate acyltransferase (GPAT) or a second LPAAT, optionally further comprising (iii) a heterologous nucleic acid encoding a DGAT; or a microorganism comprising (i) a heterologous nucleic acid encoding a first lysophosphatidic acid acyltransferase (LPAAT), and (ii) a heterologous nucleic acid encoding a second LPAAT, optionally further comprising (iii) a heterologous nucleic acid encoding a DGAT and / or GPAT; or a microorganism comprising a specific LPAAT2, optionally further comprising a heterologous nucleic acid encoding a glycerol-3-phosophate acyltransferase (GPAT), a diacylglycerol acyltransferase (DGAT), or a second LPAAT, and use for the production of triacylglycerol.

The invention relates to the technical field of grease processing, and discloses a method for increasing the sn-2 DHA content in schizochytrium limacinum triglyceride. The method comprises the following steps: adding a metabolic regulator into a fermentation culture solution containing schizochytrium limacinum, carrying out fermentation culture until the total fermentation time is more than 120 hours, and collecting a grease product, the metabolic regulator is selected from at least one of choline chloride, inositol and lysophosphatidic acid. According to the method provided by the invention, the lipid metabolic flux of schizochytrium limacinum can be effectively regulated and controlled, and directional enrichment of DHA to the sn-2 site of triglyceride is remarkably promoted, so that the yield and content of sn-2 DHA are improved.

A persistent encapsulation structure capable of preventing the degradation of bioactive substances, which encapsulation structure comprises a variety of encapsulation structure bodies (10), characterized by that the respective encapsulation structure body (10) has a polysaccharide structure (11) by which a plurality of bioactive substances (12) are encapsulated, wherein the bioactive substance (12) is selected from a group consisting of a bioactive fatty substance (121) and a bioactive non-fatty substance (122); that the polysaccharide structure (11) comprises at least one polysaccharide, wherein the at least one polysaccharide is first thoroughly mixed, then sheared at high pressure or homogenized at high speed and finally atomized dried, such that the polysaccharide structure (11) forms branched polysaccharides and linear polysaccharides which form a multitude of network structures; that the bioactive fatty substance (121) is selected from a group consisting of glycerophospholipids, sphingophospholipids, gangliosides, L-α- / glycerylphosphorylcholines, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositol, phosphatidylserines, phosphatidic acids, phosphatidylglycerol, ceramides, glucocerebrosides, glycolipids, cholesterols and fatty acid substances; and that the bioactive nonfatty substance (122) is selected from a group of coenzymes, vitamins, carotenes, carotenoids, curcuminoids, curcumin, curcumin extract, polyphenols, saponins, glycosides, terpenoids, ergothioneine, minerals, acid substances, functional polysaccharides, carbohydrates, functional proteins, peptides, amino acids and their derivatives.

The invention belongs to the technical field of molecular diagnosis, and particularly relates to a marker combination for risk assessment when an individual is exposed to electromagnetism and / or noise and application of the marker combination, and markers comprise one or more of 1-stearoyl-2-linoleoyl-sn-glycerin, 1-(9Z, 12Z-octadecadienoyl)-lysophosphatidic acid and N, N-dimethyl phosphatidyl ethanolamine (16: 0 / 16: 0). According to the present invention, the marker can significantly change in the early stage (less than or equal to 7 days) after the individual is exposed by electromagnetism and / or noise, and the abundance level of the marker in the blood sample from the individual is detected so as to rapidly achieve the early, accurate and non-invasive detection of the health risk when the individual is exposed by electromagnetism and / or noise, such that the application prospect is wide.

The invention discloses a method for identifying a sea cucumber producing area based on combination of lipidomics and machine learning, which realizes accurate identification of the sea cucumber producing area by acquiring lipidomics data and screening and identifying markers and combining a machine learning model and interpretability analysis. According to the method, triglyceride, phosphatidic acid and phosphatidyl ethanolamine are obtained through screening as lipid markers, Dalian local sea cucumber and Fujian northern sea cucumber and southern sea cucumber can be accurately distinguished, the method has the advantages of being high in accuracy, high in interpretability and good in universality, and the method can be used for sea cucumber production place identification and supervision sampling inspection; and an effective technical means is provided for aquatic product producing area traceability and identification.

The invention provides a membrane phospholipid composition specific liposome for promoting eggshell mineralization and application thereof. The liposome membrane is prepared from the following components as raw materials: (a) core membrane phospholipid; (b) an acidic phospholipid and (c) a membrane stabilizing component; wherein the core membrane phospholipid comprises PC (Polycarbonate) and PE (Polyethylene); the acidic phospholipid is PS and / or PA; the membrane stabilizing component comprises at least one of methoxy polyethylene glycol modified phosphatidyl ethanolamine (DSPE-PEG), 1, 2-dimyristoyl-rac-glycerol-3-methoxy polyethylene glycol (DMG-PEG), 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)] (DOPE-PEG), and cholesterol (Cholesterol). Through specific combination of core membrane phospholipids (PC and PE) and acidic phospholipids (PS and / or PA), an initial mineralization microenvironment in a living body is successfully simulated. In-vitro mineralization test results show that the liposome can effectively promote formation and growth of calcium carbonate crystal nucleuses, has excellent performance on interfaces of eggshell membranes, silicon wafers and the like, and proves universality and effectiveness.

The present disclosure provides compounds and pharmaceutically acceptable salts thereof that inhibit lysophosphatidic acid receptor 1 (LPA1). These compounds are useful, for example, in the treatment of diseases associated with LPA1 activity. The present disclosure also provides compositions containing the compounds as well as methods of using and making the compounds.

A process for degumming a vegetable oil comprising the steps of: a) providing a vegetable oil containing a quantity of phospholipids, b) contacting the oil with one or more phospholipases in presence of water, c) separating the reaction mixture of step b) into a light phase and a heavy phase, and d) producing a degummed vegetable oil, wherein the phospholipase has at least 75 percent sequence identity to SEQ ID NO: 1, wherein more than 75% or 85% or 90% of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) is hydrolyzed, and more than 25% or 35% or 50% of phosphatidic acid (PA) is hydrolyzed and wherein the process is carried out at a temperature of 70°C or above.

The application provides a mycoplasma hyopneumoniae culture medium capable of significantly improving the strain titer and an application thereof, and belongs to the field of veterinary biological products. The mycoplasma hyopneumoniae culture medium is obtained by adding L-asparagine, myo-inositol, arachidonic acid, urea, histamine, sodium pyruvate, valproic acid, glyceric acid, lysophosphatidic acid, L-citrulline, L-glutamine and L-leucine into a KM2 culture medium containing Bama pig serum. The culture medium can significantly improve the growth rate and viable bacterial titer of the mycoplasma hyopneumoniae under a low serum concentration, and reduces the production cost.

To provide a compound which inhibits the physiological activity of lysophosphatidic acid (LPA) and is useful as a medicine for treating or preventing diseases for which the inhibition of the physiological activity of LPA is useful.SOLUTION: Provided are compounds having the structure of Formula 1 or a pharmaceutically acceptable salt or prodrug thereof.SELECTED DRAWING: None

The invention provides a construction method and an application of recombinant yarrowia lipolytica for synthesizing furithrolin. The recombinant yarrowia lipolytica is obtained by introducing a combination of a coding gene of tenosyl ether synthase, a coding gene of cytochrome P450 oxidase, a coding gene of cytochrome P450 reductase, a coding gene of acetyltransferase, a coding gene of cytochrome b5 and a coding gene of scaffold protein, and knocking out a coding gene of phosphatidic acid phosphatase at the same time. The efficient synthesis of the fuchsin is realized. The construction method of the yarrowia lipolytica for biosynthesis of the eriolarynx element, provided by the invention, is simple to operate, and the constructed recombinant yarrowia lipolytica can efficiently produce the eriolarynx element and has relatively high production and application values.

The invention relates to the field of biomarker diagnosis, in particular to application of a novel biomarker phosphatidic acid (PA) in preparation of a marker for diagnosing immunotherapy sensitivity of a patient with esophageal squamous carcinoma. Experiments prove that whether a patient responds to immunotherapy (AUC = 0.9450) or not can be effectively diagnosed by detecting the expression quantity of PA in the plasma of the esophageal squamous carcinoma patient, and the key clinical requirements of individualized precise medical treatment and improvement of the overall curative effect are met. Therefore, the method has a wide application prospect.

Extracellular vesicles (PDEVs) for reaching the blood-brain barrier characterized by: be obtained from oranges from organic farming and to contain within the lipid membrane a ratio between the concentration of Phosphatidylethanolamine (PE) and the concentration of Phosphatidic Acid (PA) between 8 and 15.

The invention relates to the technical field of microbial oil processing, and discloses a method for increasing the content of phospholipid DHA in schizochytrium limacinum oil. The method comprises the following steps: adding a metabolic regulator into a fermentation culture solution containing schizochytrium limacinum, carrying out fermentation culture until the total fermentation time is 90-120 hours, and collecting a grease product, the metabolic regulator is selected from at least one of choline chloride, ethanolamine, inositol and lysophosphatidic acid. According to the method provided by the invention, the lipid metabolic flux of schizochytrium limacinum can be effectively regulated and controlled, and directional enrichment of DHA to phospholipid components is remarkably promoted, so that the yield and content of phospholipid DHA are improved.

The application provides an enzyme inhibiting supramolecular complex and application in cosmetics, and relates to the field of cosmetic raw materials.The supramolecular complex is a supramolecular structure formed by hydrogen bond connection of coriander glycoside and sodium phosphatide through high-pressure homogenization treatment and gradient freeze-drying treatment, and can inhibit key enzymes of sebaceous gland secretion, including aminoacylase N, 3beta-hydroxysteroid dehydrogenase and fatty acid synthase.The supramolecular complex can be added into different types of cosmetics, especially cosmetics with oil control and pore shrinking functions, so that the supramolecular complex can not only play a role of the composition itself, but also improve the transdermal rate by using the lipophilicity of phospholipid, and maximizes the cosmetic effect.

The invention discloses a preparation method of phosphatidylserine, which comprises the following steps: 1) hydrolyzing crude phospholipid by using broad-spectrum hydrolytic active phospholipase to generate phosphatidic acid; according to the method, the phosphatidylserine can be prepared by directly using the crude phospholipid, the process can be simplified, the production efficiency can be improved, and the production cost can be reduced.

The invention belongs to the technical field of biomarkers, and particularly relates to a group of markers for diagnosing RE and application thereof. The marker provided by the invention comprises diglyceride (18: 1 / 18: 1), diglyceride (18: 1 / 18: 2), diglyceride (16: 0 / 18: 2), diglyceride (16: 0 / 18: 1), phosphatidyl ethanolamine (P-16: 0 / 18: 1) and sphingosine phosphatidate 4. The six lipids are obviously disordered in saliva of an RE patient, and the RE can be quickly detected only by detecting the saliva of the patient, so that discomfort of the patient caused by invasive examination is avoided; the marker is highly related to the RE and has high accuracy in RE detection, misdiagnosis caused by subjective judgment is avoided, and a novel noninvasive technical path is provided for early screening and clinical monitoring of the RE.

The application discloses a TAT peptide modified photoredox enzyme liposome and a preparation method and application thereof, and the method comprises the following steps: S1: mixing and dispersing phosphatidylserine, dipalmitoyl phosphatidylglycerol, phosphatidic acid and glycerol to obtain a phospholipid-glycerol mixed phase; S2: dissolving photoredox enzyme and carboxymethyl chitosan, and adding the photoredox enzyme and carboxymethyl chitosan into the phospholipid-glycerol mixed phase to obtain photoredox enzyme liposomes; and S3: mixing and dispersing TAT peptides and the photoredox enzyme liposomes to obtain the TAT peptide modified photoredox enzyme liposomes; the TAT peptide modified photoredox enzyme liposomes have the advantages of mildness, non-stimulation and low cost, are non-toxic and have biological safety, have a storage stability of more than 90 days, and can effectively promote transdermal absorption of active substances in biological drugs, and thus the application range is widened.

The invention discloses a pregnancy-assisting food or health-care product containing a phosphatidic acid extract, and application of the phosphatidic acid extract in preparation of medicines for treating pregnancy disorder diseases. The phosphatidic acid extract provided by the invention can improve the quality of oocytes in an aged maternal body of an aged mouse, improve the sex hormone level of the aged mouse and improve the fertility of the aged mouse.

Lysosomal membrane permeabilization is an evolutionarily conserved hallmark of stress-induced cell death. Here the inventors show that the major stress-inducible heat shock protein 70 (Hsp70) enhances cell survival by stabilizing lysosomes through a pH-dependent high affinity binding to an endo-lysosomal anionic phospholipid bis(monoacylglycero)phosphate (BMP; also referred to as lysobisphosphatidic acid). The positively charged ATPase domain of Hsp70 is responsible for the binding but the substrate-binding domain is also required for effective stabilization of lysosomes. Importantly, the cytoprotective effect can be obtained by endocytic delivery of recombinant Hsp70 and specifically reverted by extra cellular administration of BMP antibodies or Hsp70 inhibitors. Thus, this protein-lipid interaction opens exciting possibilities for the development of cytoprotective and cytotoxic lysosome-specific therapies for the treatment of degenerative diseases and cancer, respectively.

The invention discloses an application of a rice lipid transporter protein LTPL113 in resisting fungal diseases. According to the invention, it is found for the first time that the OsLTPL113 gene participates in pollen outer wall development of rice and rice immune response by combining phosphatidic acid (PA) and phosphatidylserine (PS), including reactive oxygen species (ROS) bursting, so that the OsLTPL113 gene plays a positive regulation role in resistance of rice to Magnaporthe oryzae and Rhizoctonia solani. The invention further relates to knockout of the OsLTPL113 gene in rice and acquisition of an overexpression plant, and the broad-spectrum resistance of the overexpression plant to rice fungi is improved.

The present application relates to triazole derivatives of general formula (I) that bind to lysophosphatidic acid receptor 1 (LPAR1) and act as antagonists of LPAR1. These compounds can be used to treat diseases and / or conditions, including fibrosis and liver diseases, such as nonalcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD), by binding to LPAR1.

The application belongs to the technical field of medicine and chemical industry, and particularly relates to a synthesis method of 1,2-bifatty acyl-sn-glycerol-3-phosphatidic acid. The synthesis method of the liposome precursor compound 1,2-bifatty acyl-sn-glycerol-3-phosphatidic acid in the application is to perform a phosphorylation reaction on 1,2-bifatty acyl-sn-glycerol and phosphorus oxychloride as raw materials, and then to perform a hydrolysis reaction to obtain the required 1,2-bifatty acyl-sn-glycerol-3-phosphatidic acid. The two-step phosphorylation-hydrolysis reactions in the whole process can be performed under the bifunctional catalyst system, and the high-efficiency catalytic reaction can be realized without replacing the catalyst, and the product conversion rate is high.

According to the present invention, it is possible to develop a technique whereby lysophosphatidylcholine and lysophosphatidic acid in a cerebrospinal fluid can be analyzed with high accuracy by an analysis method comprising a step for detecting lysophosphatidylcholine and / or lysophosphatidic acid in a biological sample by mass spectrometry, and a lysophosphatidylcholine compound of which the choline part contains stable isotopes is used as a standard sample.

The application discloses a wheat Tilletia indica-specific biomarker combination, a screening method and application thereof, and the biomarker combination comprises 20-hydroxyarachidonic acid, 1-octadecyl lysophosphatidic acid, linolenic acid, 13-hydroxydocosahexaenoic acid, 4-methoxy estrone, hypoxanthine, 3-hydroxymyristic acid, beta-ecdysterone, 17-phenyltrinorprostaglandin F2 alpha cyclopropylmethylamide, 11,12-dihydroxyeicosatrienoic acid and oxidized octadecadienoic acid. When the biomarker combination is used for identifying Tilletia indica, the time-consuming long and the accuracy easily interfered by the spore development stage limitations of traditional morphological identification are overcome; in view of the molecular level identification difficulty caused by the high genome homology of Tilletia indica and Tilletia controversa, the application digs the feature difference at the level of metabolomics, and constructs a specific chemical fingerprint, so that the technical bottleneck that the close relatives are difficult to accurately distinguish is effectively solved.

Disclosed are compositions, systems, and methods involving lipid nanoparticle primarily composed of phosphatidic acid (PA), monogalactosyldiacylglycerol (MGDG), and digalactosyldiacylglycerol (DGDG). In particular, the PA, MGDG, and DGDG are present in the nanoparticles in useful ratios, preferably falling in a ratio of 3 to 7, I to 3, and 2 to 4, respectively. Further, it is useful for the PA, MGDG, and DGDG to make up 90% or more of the total lipid in the nanoparticles. The disclosed lipid nanoparticles are useful as drug delivery systems for delivery of a drug, such as oral delivery, intravascular delivery, or intramuscular delivery. The disclosed lipid nanoparticles can be used in methods involving administration or delivery of the nanoparticles to a subject. In some forms, the subject can be a disease or condition, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, cancer, colon cancer, or a coronavirus infection.

The application provides a kind of nanocarrier composition, preparation method, application and related products, belong to nucleic acid carrier technical field.The nanocarrier composition of the application includes: ionizable cationic lipid, phospholipid, cholesterol, dimyristyl glycerol-polyethylene glycol and carrier regulator;The ionizable cationic lipid is lipophilic substituted polyamine substance, and the carrier regulator is selected from at least one of stearic acid, phosphatidic acid, dioleoyl phosphatidylserine sodium.The nanocarrier provided by the application can effectively target and enrich nucleic acid into spleen, and can be used for preparing nucleic acid drug for targeted delivery.

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and / or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).

To provide a defensin expression promoter having an excellent defensin expression promoting action on the skin or in vivo.SOLUTION: Lysophosphatidic acid or its salt is used as an active ingredient. Since lysophosphatidic acid or a salt thereof has an excellent defensin expression promoting action on the skin or in vivo, it can be preferably used for the purpose of improving the antibacterial action on the skin or in vivo. It is particularly effective for promoting the expression of human β - defensin-1 and human β - defensin-3 among defensins. In addition, since lysophosphatidic acid or a salt thereof also has an action of suppressing proliferation of Propionibacterium acnes based on the action of promoting expression of human β - defensin-3, it can be used as an agent for suppressing proliferation of Propionibacterium acnes.SELECTED DRAWING: None